Tongling

Researchers are conducting a prospective observational cohort study to compare the incidence of gastric cancer and the progression of gastric precancerous lesions among groups with different Helicobacter pylori Hp genetic subtypes. The study focuses on adults aged 40 and older who have a baseline negative gastric endoscopy and are either carriers of high-risk Hp SNP subtypes, non-high-risk subtypes, or are Hp negative. The goal is to understand how these genetic differences impact gastric cancer risk over time. Participants are followed prospectively in three groups those who are Hp positive with high-risk SNP subtypes, those Hp positive with non-high-risk SNP subtypes, and those who are Hp negative. The study does not involve any treatment but monitors the natural progression of gastric conditions associated with these groups. Follow-up assessments occur over a period of up to 10 years, with primary and secondary outcomes measured at 3, 5, and 10 years. During the study, participants undergo baseline and follow-up examinations to monitor the incidence of gastric cancer and the development of precancerous lesions such as atrophic gastritis and intestinal metaplasia. Researchers also examine how factors like age, gender, diet, smoking, alcohol use, and family history might interact with Hp genetic risk. The primary outcome focuses on the difference in gastric cancer incidence among the groups during a 3-year follow-up, while secondary outcomes consider longer-term incidence and lesion progression. Participants safety and ability to continue in the study are monitored throughout the follow-up period.

Researchers are establishing a standardized clinical database for patients with liver cancer, including hepatocellular carcinoma and related types, to support high-quality real-world clinical studies. This observational study is led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China USTC in collaboration with multiple centers nationwide. The purpose is to collect detailed clinical information to better understand liver cancer outcomes over time. Participants will receive routine clinical treatments for liver cancer, such as surgical resection, ablation, transarterial chemoembolization TACE, hepatic arterial infusion chemotherapy HAIC, and various anti-tumor drugs including immunologic, targeted, and chemotherapy agents. The study observes and records these standard treatments without assigning interventions. The research will track these patients in a cohort database to monitor their treatment and progression. During the study, participants will be followed for up to 10 years to assess overall survival, recurrence-free survival, and survival time after cancer recurrence. Researchers will collect blood and surgical tissue samples and perform regular follow-up visits to gather clinical data and pathology results. This long-term monitoring aims to provide comprehensive insights into liver cancer progression and treatment outcomes.

Researchers are conducting a prospective study to compare two methods for early detection of gastric cancer fecal Helicobacter pylori gastric cancer susceptibility testing and a gastric cancer risk questionnaire. The goal is to see if either method alone or combined can help diagnose gastric cancer earlier. This study involves adults aged 40 years and older from selected communities in Tongling City. Participants will provide stool samples for molecular testing to detect specific genetic markers linked to gastric cancer risk from H. pylori infection. They will also complete a detailed questionnaire about their gastric cancer risk. Those who test positive on either method will be referred for confirmatory diagnostic procedures, including fiberoptic endoscopy and biopsy. Individuals without a cancer diagnosis in the first year will enter an annual follow-up program. Residual stool samples will be stored for future biomarker research. Throughout the study, participants will undergo screening and risk assessment, followed by diagnostic workups if indicated. Researchers will monitor the accuracy of the testing methods over two years, measuring sensitivity, specificity, predictive values, and the rate of early gastric cancer diagnosis. The study will track participants health and collect data to evaluate how well these tools identify gastric cancer early, aiming to improve detection strategies.

Researchers are evaluating a multi-target fecal DNA test combined with a gastric cancer risk questionnaire to detect gastric cancer early. This prospective study aims to assess whether detecting Helicobacter pylori genes and fecal methylated DNA markers, individually or together, can help diagnose gastric cancer sooner. The study is conducted by Fudan University and involves residents from selected communities in Tongling City. Participants who join will provide stool samples for the multi-target DNA test and complete a risk questionnaire. Those who test positive on the fecal DNA test or are identified as high-risk by the questionnaire will undergo further diagnostic workup, including fiberoptic endoscopy and pathological biopsy. Individuals not diagnosed with gastric cancer in the first year will enter an annual follow-up program. Residual stool samples will be stored for future biomarker research. During the study, participants will be interviewed face-to-face to complete the questionnaire and provide stool samples. Researchers will measure the sensitivity, specificity, predictive values, and diagnosis rates related to the fecal DNA test and questionnaire over two years. The study will monitor participants through follow-up visits and evaluate outcomes related to early gastric cancer detection and precancerous lesion diagnosis.

Researchers are studying patients who have had an acute ischemic stroke caused by a blockage in a large blood vessel in the brain. The trial focuses on the safety and effectiveness of remote ischemic conditioning RIC as an additional treatment to improve recovery after endovascular thrombectomy, a procedure that removes the blockage. This research addresses the challenge that even when blood flow is restored, many patients still have poor outcomes or die, possibly due to brain injury during and after the procedure. The study compares three groups one receiving only endovascular thrombectomy and best medical care, a second group receiving thrombectomy plus RIC treatment for 14 days, and a third group receiving thrombectomy plus RIC for 30 days. RIC is a noninvasive device treatment where a cuff on the upper arm inflates and deflates in cycles, applied once before thrombectomy and twice daily afterward. Best medical management follows clinical guidelines for all groups. Participants will be monitored closely for 90 days after stroke. Researchers will assess recovery using the modified Rankin Scale to measure functional independence and will record neurological improvements, brain infarct size, adverse events, and quality of life. The study includes imaging, neurological exams, and safety checks at multiple time points, including 24 hours, 14 days, 72 hours, and 90 days post-treatment to evaluate the impact of RIC on stroke outcomes.

Researchers are evaluating the safety and effectiveness of TQC2731 injection in adults with severe asthma that is not well controlled. This is a Phase III clinical trial where 660 participants with asthma are randomly assigned to receive either TQC2731 or a placebo. The study aims to see if TQC2731 can reduce asthma worsening episodes over one year compared to placebo. Participants receive either the TQC2731 injection or placebo every four weeks for up to 48 weeks through subcutaneous injection. The treatment cycles repeat monthly from the start until Week 48. The study compares these two groups to assess the impact on asthma symptoms and lung function. Throughout the trial, participants will have regular assessments including lung function tests, asthma symptom diaries, quality of life questionnaires, and blood tests for inflammation markers and immune response. Researchers track the number of asthma exacerbations during the 52 weeks of treatment and up to 64 weeks for some outcomes. Safety and immune reactions are monitored carefully. The total study duration for each participant is about one year of treatment plus follow-up.